You are here: Home: PCU 2 | 2006: Case 5: Select publications

SELECT PUBLICATIONS

Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis 2006;[Epub ahead of print]. Abstract

Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337(5):295-300. Abstract

Chodak GW, Warren KS. Watchful waiting for prostate cancer: A review article. Prostate Cancer Prostatic Dis 2006;9(1):25-9. Abstract

D’Amico AV et al. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23(22):4975-9. Abstract

D’Amico AV et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294(4):440-7. Abstract

D’Amico AV et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125-35. Abstract

Kaisary AV. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis 2005;8(2):140-51. Abstract

Kirby R. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation. Nat Clin Pract Urol 2005;2(6):304-8. Abstract

Kirby R. Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nat Clin Pract Urol 2005;2(6):298-303. Abstract

Klotz L, Schellhammer P. Combined androgen blockade: The case for bicalutamide. Clin Prostate Cancer 2005;3(4):215-9. Abstract

Lee AK, D’Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005;23(32):8192-7. Abstract

Sengupta S et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174(6):2191-6. Abstract

Ward JF. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refrac­tory, metastatic prostate cancer? Nat Clin Pract Urol 2006;3(6):310-1. No abstract available

 

 

 

 

 

 

Home